Clinical Trials Browser

Phase 2 × Emapalumab × 30 days × Clear all

NCT07567014 2026-05-06

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

Phase 2 Not yet recruiting

Multiple Myeloma